What is BioSig Technologies Inc's earnings per share (EPS)?

BioSig Technologies Inc (BSGM) reported diluted earnings per share of -$9.65 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BioSig Technologies Inc (BSGM) Financials

BSGM

FY2025 annual

Revenue Not reported for FY2025

Net Income -$462.8M YoY not available

EPS (Diluted) -$9.65 YoY not available

Operating Cash Flow -$10.4M YoY not available

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BSGM SEC filings page.

This page shows BioSig Technologies Inc (BSGM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BSGM FY2025 2026-08-29

The business’s dominant mechanic is a balance-sheet reset funded externally while operating activity remains too small to explain reported losses.

The striking disconnect is that FY2025 net loss reached -$462.8M while operating loss was -$71.1M; the reported result was therefore dominated by items outside operating performance, although the tables do not identify them. Operating cash flow was -$10.4M, far less negative than net income, so the accounting loss did not translate proportionally into cash outflow.

Equity changed structurally: it moved from -$1.5M in FY2024 to $133.2M in FY2025. Financing cash flow of $54.9M alongside a 1.7x current ratio indicates that the improved balance-sheet position was tied more to financing activity than accumulated operating earnings.

The cost structure also shifted: FY2025 R&D was only $31K against SG&A of $67.5M, suggesting spending was concentrated outside development. Meanwhile, goodwill represented 37.8% of total assets, so positive equity depended materially on an intangible balance-sheet asset rather than solely on liquid or operating resources.

Financial Health Signals

Financial health score not available

BioSig Technologies Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/5

BioSig Technologies Inc passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

BioSig Technologies Inc reported a net loss of $462.8M while operations used $10.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

BioSig Technologies Inc reported an operating loss of $71.1M against $1.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$34.3M

YoY-1056.1%

BioSig Technologies Inc's EBITDA was -$34.3M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1056.1% from the same quarter a year earlier.

Net Income

-$46.7M

YoY-1560.5%

BioSig Technologies Inc reported -$46.7M in net income in Q1 2026. This represents a decrease of 1560.5% from the same quarter a year earlier.

EPS (Diluted)

-$0.27

BioSig Technologies Inc earned -$0.27 per diluted share (EPS) in Q1 2026.

Revenue

Not reported for Q1 2026.

Cash & Balance Sheet

Cash & Debt

$6.9M

YoY+84.0%

QoQ-66.2%

BioSig Technologies Inc held $6.9M in cash as of Q1 2026; long-term debt is not reported for that period.

Shares Outstanding

98M

5Y CAGR+25.2%

10Y CAGR+18.9%

BioSig Technologies Inc had 98M shares outstanding in Q1 2026.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Return on Equity

-29.4%

YoY+78.6pp

BioSig Technologies Inc's ROE was -29.4% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is up 78.6 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q1 2026.

Operating Margin

Not reported for Q1 2026.

Net Margin

Not reported for Q1 2026.

Capital Allocation

R&D Spending

$6K

YoY0.0%

BioSig Technologies Inc invested $6K in research and development in Q1 2026. That is unchanged from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

BSGM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BSGM quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Revenue	N/A	N/A	$40K+122.2%	$18K-93.7%	$286K-35.1%	$441K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	$57K-71.4%	$199K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	$18K-92.1%	$229K-5.4%	$242K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$31K-96.3%	$832K-83.7%	$5.1M-12.5%	$5.8M+3.9%	$5.6M-69.1%	$18.1M+86.2%	$9.7M+122.9%	$4.4M-8.2%	$4.8M+79.2%	$2.7M+76.1%	$1.5M0.0%	$1.5M+51.9%	$992K
SG&A Expenses	N/A	$67.5M	N/A	N/A	N/A	$27.9M-32.0%	$41.0M+65.1%	$24.8M+92.6%	$12.9M+58.3%	$8.1M	N/A	N/A	N/A	N/A
Operating Income	N/A	-$71.1M	N/A	N/A	N/A	-$33.4M+43.5%	-$59.2M-71.0%	-$34.6M-100.5%	-$17.3M	N/A	N/A	N/A	N/A	N/A
EBITDA	N/A	-$67.6M	N/A	N/A	N/A	-$33.2M+43.8%	-$59.1M-71.0%	-$34.5M-100.3%	-$17.2M	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	$1.6M+14645.5%	-$11K-222.2%	$9K+200.0%	$3K+50.0%	$2K-95.6%	$45K-66.2%	$133K+1120.5%	$11K+14429.3%	$75+7400.0%	$1+100.1%	-$1K+88.2%	-$11K+84.3%	-$70K
Income Tax	N/A	-$1.3M	$0	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$462.8M	N/A	N/A	N/A	-$31.9M+38.9%	-$52.2M-53.3%	-$34.1M-87.8%	-$18.1M	N/A	N/A	N/A	N/A	N/A
EPS (Basic)	N/A	-$9.65-1186.7%	-$0.75+81.0%	-$3.95+37.6%	-$6.33	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$9.65	-$0.75	-$3.95+37.6%	-$6.33	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	48M	14M	7M+70.7%	4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$13K
R&D Expenses	$6K0.0%	N/A	$6K-96.2%	$19K-94.4%	$6K-97.5%	N/A	$156K-86.4%	$342K-80.0%
SG&A Expenses	$34.3M+1058.4%	N/A	$4.6M+67.2%	$19.8M+302.8%	$3.0M+2.6%	N/A	$2.8M-1.8%	$4.9M-46.0%
Operating Income	-$35.7M-1097.9%	N/A	-$6.1M-107.2%	-$20.4M-284.8%	-$3.0M+13.2%	N/A	-$3.0M+27.2%	-$5.3M+51.5%
EBITDA	-$34.3M-1056.1%	N/A	-$4.6M-58.4%	-$19.8M-277.9%	-$3.0M+11.8%	N/A	-$2.9M+26.3%	-$5.2M+51.5%
Interest Expense	$12.2M	N/A	-$10K	$13K+360.0%	N/A	N/A	N/A	-$5K-266.7%
Income Tax	-$565K	N/A	-$765K	N/A	N/A	N/A	N/A	N/A
Net Income	-$46.7M-1560.5%	N/A	-$15.6M-714.2%	-$20.4M-420.4%	-$2.8M+17.3%	N/A	-$1.9M+58.1%	-$3.9M+64.7%
EPS (Basic)	-$0.27-92.9%	N/A	-$0.47-291.7%	-$0.74-146.7%	-$0.14+61.1%	N/A	-$0.12+80.3%	-$0.30+81.0%
EPS (Diluted)	-$0.27	N/A	-$0.47	-$0.74	-$0.14	N/A	-$0.12	-$0.30
Diluted Shares (Avg)	175M	N/A	33M	28M	21M	N/A	16M	13M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

BSGM Balance Sheet

BSGM quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Total Assets	$187.5M+22173.5%	$842K-53.2%	$1.8M-56.3%	$4.1M-73.5%	$15.5M-48.9%	$30.4M+113.7%	$14.2M+184.5%	$5.0M+193.9%	$1.7M+36.9%	$1.2M+20.5%	$1.0M+191.7%	$353K+0.4%	$352K
Current Assets	$71.9M+18429.6%	$388K-26.5%	$528K-53.2%	$1.1M-91.9%	$13.9M-52.6%	$29.3M+128.7%	$12.8M+177.1%	$4.6M+178.1%	$1.7M+39.9%	$1.2M+20.9%	$985K+212.2%	$315K+4.3%	$302K
Cash & Equivalents	$20.3M+14195.8%	$142K-29.0%	$200K-50.0%	$400K-96.6%	$11.7M-58.6%	$28.3M+133.5%	$12.1M+172.1%	$4.5M+187.5%	$1.5M+46.6%	$1.1M+10.8%	$953K+297.5%	$240K-20.7%	$302K
Short-Term Investments	$9.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Inventory	N/A	N/A	N/A	$336K-82.1%	$1.9M+144.9%	$768K+32.9%	$578K	$0	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$109K+354.2%	$24K+166.7%	$9K	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$165K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$71.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$54.2M+2294.7%	$2.3M-51.7%	$4.7M+26.2%	$3.7M+25.7%	$3.0M-42.2%	$5.1M+66.4%	$3.1M+156.4%	$1.2M-75.8%	$5.0M+22.9%	$4.0M+2.2%	$3.9M+0.1%	$3.9M-25.9%	$5.3M
Current Liabilities	$42.8M+1790.2%	$2.3M-50.6%	$4.6M+40.5%	$3.3M+26.6%	$2.6M-49.6%	$5.1M+151.6%	$2.0M+69.5%	$1.2M-69.8%	$4.0M+34.0%	$3.0M+19.8%	$2.5M+101.6%	$1.2M-59.4%	$3.0M
Non-Current Liabilities	$11.4M	$0-100.0%	$103K-77.2%	$452K+19.6%	$378K+37700.0%	$1K-100.0%	$2.3M+95.5%	$1.2M+21.6%	$985K-7.9%	$1.1M-27.3%	$1.5M-45.7%	$2.7M+18.0%	$2.3M
Total Equity	$133.2M+8726.4%	-$1.5M+48.8%	-$3.0M-1064.2%	$313K-97.4%	$12.2M-49.8%	$24.4M+118.6%	$11.1M+235.3%	$3.3M+202.3%	-$3.2M-16.6%	-$2.8M+4.2%	-$2.9M+18.8%	-$3.6M+27.8%	-$5.0M
Retained Earnings	-$718.1M-181.2%	-$255.3M-4.2%	-$245.0M-13.4%	-$216.0M-14.3%	-$188.9M-20.3%	-$157.0M-49.8%	-$104.8M-48.1%	-$70.7M-25.1%	-$56.5M-29.0%	-$43.8M-35.9%	-$32.2M-41.5%	-$22.8M-62.6%	-$14.0M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Total Assets	$173.3M+3823.0%	$187.5M+22173.5%	$130.5M+9104.1%	$109.7M+3431.4%	$4.4M+178.0%	$842K-53.2%	$1.4M-55.0%	$3.1M-23.3%
Current Assets	$45.9M+1051.6%	$71.9M+18429.6%	$15.0M+1667.9%	$3.0M+25.8%	$4.0M+438.6%	$388K-26.5%	$848K-19.3%	$2.4M+20.1%
Cash & Equivalents	$6.9M+84.0%	$20.3M+14195.8%	$11.0M+1695.9%	$2.8M+34.0%	$3.7M+795.9%	$142K-29.0%	$615K+53.8%	$2.1M+61.8%
Accounts Receivable	N/A	N/A	N/A	N/A	$109K+678.6%	$109K+354.2%	$81K+478.6%	$54K+157.1%
Goodwill	$69.8M	$71.0M	$69.9M	$58.7M	N/A	N/A	N/A	N/A
Total Liabilities	$14.0M+732.1%	$54.2M+2294.7%	$137.3M+7973.8%	$113.2M+3684.7%	$1.7M-71.0%	$2.3M-51.7%	$1.7M-58.6%	$3.0M-17.2%
Current Liabilities	$3.3M+96.7%	$42.8M+1790.2%	$125.6M+7283.9%	$113.2M+3703.8%	$1.7M-67.9%	$2.3M-50.6%	$1.7M-56.5%	$3.0M-10.7%
Non-Current Liabilities	$10.7M	$11.4M	$11.7M	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$15K-94.7%
Total Equity	$159.0M+6003.1%	$133.2M+8726.4%	-$7.0M-1618.3%	-$3.6M-60183.3%	$2.6M+160.3%	-$1.5M+48.8%	-$405K+65.1%	-$6K-102.5%
Retained Earnings	-$764.8M-196.3%	-$718.1M-181.2%	-$294.1M-15.7%	-$278.5M-10.4%	-$258.2M-3.9%	-$255.3M-4.2%	-$254.2M-6.4%	-$252.3M-7.7%

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Long-Term Debt.

BSGM Cash Flow Statement

BSGM quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Operating Cash Flow	-$19.5M	-$10.4M	N/A	N/A	N/A	-$26.4M+0.8%	-$26.6M-71.8%	-$15.5M-51.0%	-$10.3M-37.3%	-$7.5M-46.3%	-$5.1M-12.9%	-$4.5M	N/A	N/A
Depreciation & Amortization	N/A	$3.5M+1779.8%	$188K-47.9%	$361K+23.2%	$293K+48.0%	$198K+110.6%	$94K+74.1%	$54K+335.4%	$12K+6.0%	$12K+11.7%	$10K0.0%	$10K-33.7%	$16K-7.3%	$17K
Stock-Based Compensation	N/A	$869K-87.5%	$7.0M+2924.8%	$230K-94.8%	$4.4M	$0-100.0%	$1.3M	$0-100.0%	$6.6M+39.0%	$4.7M-20.8%	$6.0M-24.7%	$8.0M+38.7%	$5.7M+73.8%	$3.3M
Capital Expenditures	N/A	N/A	N/A	$186K+10.7%	$168K-69.0%	$542K+523.0%	$87K-50.8%	$177K+365.4%	$38K+303.1%	$9K-42.0%	$16K+2.5%	$16K+300.3%	$4K-66.2%	$12K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$26.9M-0.9%	-$26.7M-70.4%	-$15.7M-52.1%	-$10.3M-37.6%	-$7.5M-46.0%	-$5.1M-12.9%	-$4.5M	N/A	N/A
Investing Cash Flow	N/A	-$24.3M	N/A	-$186K-10.7%	-$168K+69.0%	-$542K-523.0%	-$87K+69.5%	-$285K+7.4%	-$308K-3160.7%	-$9K+42.0%	-$16K+12.0%	-$18K-366.2%	-$4K+66.2%	-$12K
Financing Cash Flow	$48.5M	$54.9M	N/A	N/A	$10.6M+2.3%	$10.3M-75.9%	$42.8M+82.9%	$23.4M+74.0%	$13.5M+68.9%	$8.0M+52.5%	$5.2M	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Operating Cash Flow	-$10.2M-812.9%	-$3.0M-537.3%	-$5.0M-237.3%	-$1.3M+13.7%	-$1.1M+15.1%	-$474K+83.9%	-$1.5M+61.1%	-$1.5M+69.7%
Depreciation & Amortization	$1.5M+7004.8%	N/A	$1.5M+4700.0%	$554K+1030.6%	$21K-73.1%	N/A	$31K-66.3%	$49K-46.7%
Stock-Based Compensation	$54-100.0%	N/A	N/A	N/A	$2.1M+95.5%	N/A	N/A	N/A
Investing Cash Flow	-$1.5M	-$24.5M	-$145K	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	-$1.6M-134.8%	$36.8M+3677900.0%	$13.4M	$0-100.0%	$4.7M+205.2%	$1K-100.0%	$0-100.0%	$3.2M-34.1%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

BSGM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BSGM quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Gross Margin	N/A	N/A	100.0%+19.9pp	80.1%+25.2pp	54.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	-7576.2%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	-7237.4%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-347.4%	N/A	N/A	N/A	-260.7%-46.5pp	-214.3%+91.3pp	-305.5%+240.0pp	-545.6%	N/A	N/A	N/A	N/A	N/A
Return on Assets	-246.8%	N/A	N/A	N/A	-205.7%-33.8pp	-171.8%+67.7pp	-239.5%+123.4pp	-363.0%	N/A	N/A	N/A	N/A	N/A
Current Ratio	1.68+1.5x	0.17+0.1x	0.12-0.2x	0.35-5.0x	5.39-0.3x	5.74-0.6x	6.32+2.5x	3.87+3.4x	0.420.0x	0.400.0x	0.40+0.1x	0.26+0.2x	0.10
Debt-to-Equity	0.41	N/A	N/A	11.86+11.6x	0.240.0x	0.21-0.1x	0.28-0.1x	0.36	N/A	N/A	N/A	N/A	N/A
Asset Turnover	N/A	0.050.0x	0.01-0.1x	0.070.0x	0.030.0x	0.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	-6109.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-40707.7%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-30115.4%
Return on Equity	-29.4%+78.6pp	N/A	N/A	N/A	-107.9%	N/A	N/A	N/A
Return on Assets	-26.9%+36.7pp	N/A	-11.9%+123.0pp	-18.6%+107.4pp	-63.6%+150.5pp	N/A	-135.0%+9.8pp	-126.0%+147.9pp
Current Ratio	13.90+11.5x	1.68+1.5x	0.12-0.4x	0.03-0.8x	2.37+2.2x	0.17+0.1x	0.50+0.2x	0.80+0.2x
Debt-to-Equity	0.09-0.6x	0.41	N/A	N/A	0.64	N/A	N/A	N/A
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
BioSig Technologies Inc BSGM	FY2025	N/A	-$462.8M	N/A	$215.2M	—
Cvrx, Inc. CVRX	FY2025	$56.7M	-$53.3M	-94.1%	$75.4M	50/100
908 Devices Inc. MASS	FY2025	$56.2M	$19.5M	34.7%	$400.5M	58/100
Outset Medical, Inc. OM	FY2025	$119.5M	-$81.7M	-68.3%	$62.2M	61/100
TriSalus Life Sciences Inc. TLSI	FY2025	$45.2M	-$39.2M	-86.9%	$293.1M	50/100
Monogram Orthopaedics Inc MGRM	FY2024	N/A	-$16.3M	N/A	$243.8M	—

Where BioSig Technologies Inc Ranks

Frequently Asked Questions

Is BioSig Technologies Inc profitable?

No, BioSig Technologies Inc (BSGM) reported a net income of -$462.8M in fiscal year 2025.

What is BioSig Technologies Inc's EBITDA?

BioSig Technologies Inc (BSGM) had EBITDA of -$67.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is BioSig Technologies Inc's return on equity (ROE)?

BioSig Technologies Inc (BSGM) has a return on equity of -347.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is BioSig Technologies Inc's operating cash flow?

BioSig Technologies Inc (BSGM) recorded an outflow of $10.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are BioSig Technologies Inc's total assets?

BioSig Technologies Inc (BSGM) had $187.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does BioSig Technologies Inc spend on research and development?

BioSig Technologies Inc (BSGM) invested $31K in research and development during fiscal year 2025.

How many shares does BioSig Technologies Inc have outstanding?

BioSig Technologies Inc (BSGM) had 50M shares outstanding as of fiscal year 2025.

What is BioSig Technologies Inc's current ratio?

BioSig Technologies Inc (BSGM) had a current ratio of 1.68 as of fiscal year 2025, which is generally considered healthy.

What is BioSig Technologies Inc's debt-to-equity ratio?

BioSig Technologies Inc (BSGM) had a debt-to-equity ratio of 0.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is BioSig Technologies Inc's return on assets (ROA)?

BioSig Technologies Inc (BSGM) had a return on assets of -246.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does BioSig Technologies Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, BioSig Technologies Inc (BSGM) held $30.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.4M over that year. Dividing the one by the other, the reported balance equals about 35 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is BioSig Technologies Inc's Piotroski F-Score?

BioSig Technologies Inc (BSGM) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BioSig Technologies Inc's earnings high quality?

BioSig Technologies Inc (BSGM) reported a net loss of $462.8M while operations used $10.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can BioSig Technologies Inc cover its interest payments?

BioSig Technologies Inc (BSGM) reported an operating loss of $71.1M against $1.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.